EMA — authorised 29 October 2012
- Application: EMEA/H/C/002250
- Marketing authorisation holder: Pfizer Ltd.
- Local brand name: Elelyso
- Indication: treatment of Gaucher disease
- Pathway: orphan
- Status: rejected
🇪🇺 Elelyso in European Union
EMA authorised Elelyso on 29 October 2012
Marketing authorisations
EMA
- Status: approved
Elelyso in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Rare Disease approved in European Union
Frequently asked questions
Is Elelyso approved in European Union?
Yes. EMA authorised it on 29 October 2012; EMA has authorised it.
Who is the marketing authorisation holder for Elelyso in European Union?
Pfizer Ltd. holds the EU marketing authorisation.